The anti-obesity effects of postbiotics: A systematic review of pre-clinical and clinical studies

IF 2.9 Q3 NUTRITION & DIETETICS

Clinical nutrition ESPEN Pub Date : 2024-10-25 DOI:10.1016/j.clnesp.2024.10.153

Maysa Eslami , Azin Pakmehr , Farzad Pourghazi , Atefe Kami , Hanieh-Sadat Ejtahed , Mohammadreza Mohajeri-Tehrani , Shirin Hasani-Ranjbar , Bagher Larijani

{"title":"The anti-obesity effects of postbiotics: A systematic review of pre-clinical and clinical studies","authors":"Maysa Eslami , Azin Pakmehr , Farzad Pourghazi , Atefe Kami , Hanieh-Sadat Ejtahed , Mohammadreza Mohajeri-Tehrani , Shirin Hasani-Ranjbar , Bagher Larijani","doi":"10.1016/j.clnesp.2024.10.153","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The growing prevalence of obesity has become a major concern worldwide, therefore a great number of studies are conducted every day in the field of obesity. Since postbiotics are a newly introduced term, there is not much systematic evidence about their function and impact on obesity. We designed this study to systematically review the effect of different types of postbiotics on obesity.</div></div><div><h3>Methods</h3><div>A systematic search was conducted using PubMed, SCOPUS, and Web of Science databases up to August 2023. Both human and animal interventional studies that investigated the effects of any type of postbiotic on obesity and obesity-related factors were eligible. Screening, data extraction, and quality assessment were conducted independently by two researchers. The quality of the studies was appraised using Cochrane and Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE's) risk of bias tool.</div></div><div><h3>Results</h3><div>Of the 19373 retrieved studies, finally, 49 studies were included (9 human studies and 40 animal studies). Short-chain fatty acids and heat-killed (inactivated) bacteria were the most used postbiotics. In human clinical trials, inactivated <em>Lactobacillus amylovorus</em> (CP1563), <em>Bifidobacterium animalis</em> subsp. <em>lactis</em> (CECT 8145) and <em>Pediococcus pentosaceus</em> (LP28) were administered orally as postbiotics which improved body composition and anthropometric indices. Animal studies evaluated other types of postbiotics including muramyl dipeptide, cell-free extracts, urolithin A&B, extracellular Vesicles, exopolysaccharides, and surface Layer Proteins, supporting the anti-obesity effects of postbiotics.</div></div><div><h3>Conclusion</h3><div>Postbiotics seem to be a safe intervention and the results were in favor of a reduction in adipogenesis as well as an increase in energy expenditure. Further high-quality studies are required in this relatively new topic.</div></div>","PeriodicalId":10352,"journal":{"name":"Clinical nutrition ESPEN","volume":"64 ","pages":"Pages 370-389"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition ESPEN","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405457724014918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The growing prevalence of obesity has become a major concern worldwide, therefore a great number of studies are conducted every day in the field of obesity. Since postbiotics are a newly introduced term, there is not much systematic evidence about their function and impact on obesity. We designed this study to systematically review the effect of different types of postbiotics on obesity.

Methods

A systematic search was conducted using PubMed, SCOPUS, and Web of Science databases up to August 2023. Both human and animal interventional studies that investigated the effects of any type of postbiotic on obesity and obesity-related factors were eligible. Screening, data extraction, and quality assessment were conducted independently by two researchers. The quality of the studies was appraised using Cochrane and Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE's) risk of bias tool.

Results

Of the 19373 retrieved studies, finally, 49 studies were included (9 human studies and 40 animal studies). Short-chain fatty acids and heat-killed (inactivated) bacteria were the most used postbiotics. In human clinical trials, inactivated Lactobacillus amylovorus (CP1563), Bifidobacterium animalis subsp. lactis (CECT 8145) and Pediococcus pentosaceus (LP28) were administered orally as postbiotics which improved body composition and anthropometric indices. Animal studies evaluated other types of postbiotics including muramyl dipeptide, cell-free extracts, urolithin A&B, extracellular Vesicles, exopolysaccharides, and surface Layer Proteins, supporting the anti-obesity effects of postbiotics.

Conclusion

Postbiotics seem to be a safe intervention and the results were in favor of a reduction in adipogenesis as well as an increase in energy expenditure. Further high-quality studies are required in this relatively new topic.

查看原文本刊更多论文

益生菌的抗肥胖作用：临床前和临床研究的系统回顾。

背景：肥胖症的发病率越来越高，已成为全世界关注的一个主要问题，因此，每天都有大量关于肥胖症的研究在进行。由于益生菌是一个新引入的术语，关于其功能和对肥胖的影响的系统性证据并不多。我们设计了这项研究，以系统回顾不同类型的益生菌对肥胖的影响：方法：我们使用 PubMed、SCOPUS 和 Web of Science 数据库对截至 2023 年 8 月的研究进行了系统检索。研究任何类型的益生菌对肥胖和肥胖相关因素影响的人类和动物干预性研究均符合条件。筛选、数据提取和质量评估由两名研究人员独立完成。研究质量采用 Cochrane 和实验动物实验系统综述中心（SYRCLE）的偏倚风险工具进行评估：在检索到的 19373 项研究中，最终纳入了 49 项研究（9 项人类研究和 40 项动物研究）。使用最多的益生菌是短链脂肪酸和热杀死（灭活）细菌。在人体临床试验中，口服灭活的淀粉乳杆菌（CP1563）、动物双歧杆菌亚种（CECT 8145）和五味子球菌（LP28）作为益生元，可改善身体组成和人体测量指数。动物研究评估了其他类型的益生元，包括氨酰二肽、无细胞提取物、尿石素 A 和 B、细胞外囊泡、外多糖和表面层蛋白，支持益生元的抗肥胖作用：结论：益生菌后似乎是一种安全的干预措施，其结果有利于减少脂肪生成和增加能量消耗。对于这个相对较新的课题，还需要进一步开展高质量的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nutrition ESPEN NUTRITION & DIETETICS-

CiteScore

4.90

自引率

3.30%

发文量

512

期刊介绍： Clinical Nutrition ESPEN is an electronic-only journal and is an official publication of the European Society for Clinical Nutrition and Metabolism (ESPEN). Nutrition and nutritional care have gained wide clinical and scientific interest during the past decades. The increasing knowledge of metabolic disturbances and nutritional assessment in chronic and acute diseases has stimulated rapid advances in design, development and clinical application of nutritional support. The aims of ESPEN are to encourage the rapid diffusion of knowledge and its application in the field of clinical nutrition and metabolism. Published bimonthly, Clinical Nutrition ESPEN focuses on publishing articles on the relationship between nutrition and disease in the setting of basic science and clinical practice. Clinical Nutrition ESPEN is available to all members of ESPEN and to all subscribers of Clinical Nutrition.